New Drowzee Company Logo 2019 Trondheim Norway

Biomedical/Product Engineer

  • Full Time
  • Oslo, Norway
  • Applications have closed

 

Drowzee envisions a healthier and more capable future society. Helping people sleep better is a catalyst.

The team is driven by a desire to solve problems for the benefit of humanity. By working as one collective organism with high commitment towards the vision we can make a real world impact.

Are you looking to be a part of a team with ambitious and hard-working members? If you are motivated by big challenges, curious by nature, structured and consider yourself a doer, let’s talk.

 

Position Attributes

  • Full Time
  • Location – Oslo: Candidate can work remotely for a period of 6 months, after which the need to relocate will be reevaluated
  • Experience required: 3-5 years
  • Compensation : Fixed salary + Equity

 

Key Qualifications

  • Solving a biological problem using BCIs and/or medical devices.
  • Built front-end applications for end users (modern mobile frameworks/technologies).
  • Built integrated HW/SW systems.

 

Preferred Qualifications

  • Biohacking (it’s a plus if in the field of sleep or sleep-related).
  • Worked in start-up and/or industry (experience outside academia).
  • Being part of feedback loops with end users.

 

Personal Skills

  • Motivated by big challenges.
  • Ability to lead and follow.
  • Exceptional team working skills and ability to work independently.
  • Structured, systematic and delivers on your responsibilities.
  • Work fast and build solutions that work in practice.

 

We Offer

  • Opportunity to work on solving a worldwide problem.
  • Chance to be a part of the neurotechnology revolution.
  • Prospect of being part of a high-performing environment.
  • Competitive base salary, equity, and freedom to work productively.
  • Office premise and necessary equipment.
  • Free essential medical and care services.
  • Insurance & pension.

 

Tagged as: AI, BCI, EEG, Machine Learning, Neuroscience

No Comments

Sorry, the comment form is closed at this time.